Home › NDC Lookup › RxCUI directory › RxCUI 829500

Mefenamic acid 250 MG Oral Capsule — RxCUI 829500

RxNorm drug concept · Semantic clinical drug
RxCUI 829500 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI829500
Official nameMefenamic acid 250 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped6
Package NDCs mapped11
Reported Medicaid activity (SDUD)1,776 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mefenamic Acid: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mefenamic acid is used for two things: short-term mild to moderate pain (no more than 7 days) and painful menstrual periods (primary dysmenorrhea). It's approved for people 14 year...
  • What is mefenamic acid actually used for?
  • For menstrual cramps, you start taking mefenamic acid capsules at the first sign of bleeding and cramping. You take a larger starting dose first, then a smaller dose every 6 hours....
  • The most common side effects are stomach-related — nausea, diarrhea, heartburn, and stomach pain. Headache and dizziness can also happen. Those are uncomfortable but usually manage...
📖 Read our full Mefenamic Acid guide →

🕸️ Concept Web — How Mefenamic acid 250 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mefenamic acid 250 MG Oral Capsule RxCUI 829500

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Mefenamate 257844
    • Mefenamic acid 6693
  2. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mefenamate Oral Capsule 618388
    • Mefenamic acid Oral Capsule 2649524
    • Mefenamate Oral Product 1159197
    • Mefenamate Pill 1159198
    • Mefenamic acid Oral Product 2663551
    • Mefenamic acid Pill 2660777
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Mefenamic acid 250 MG 829499

Showing up to 8 concepts per family — 11 of 12 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mefenamic acid 250 MG SCDC · 829499
  • Mefenamate Oral Capsule SCDF · 618388
  • Mefenamic acid Oral Capsule SCDFP · 2649524
  • Mefenamate Oral Product SCDG · 1159197
  • Mefenamate Pill SCDG · 1159198
  • Mefenamic acid Oral Product SCDGP · 2663551
  • Mefenamic acid Pill SCDGP · 2660777

📦 FDA Products & Package NDCs

6 products · 11 package NDCs
11 package NDCs map to RxCUI 829500 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00276-0509-30 30 CAPSULE in 1 BOTTLE (0276-0509-30) Mefenamic Acid Misemer Pharmaceuticals, Inc 2021-11-01
42571-0258-01 100 CAPSULE in 1 BOTTLE (42571-258-01) Mefenamic acid Micro Labs Limited 2010-11-19
42571-0258-30 30 CAPSULE in 1 BOTTLE (42571-258-30) Mefenamic acid Micro Labs Limited 2010-11-19
68180-0185-06 30 CAPSULE in 1 BOTTLE (68180-185-06) Mefenamic Acid Lupin Pharmaceuticals, Inc. 2011-09-06
72162-2382-03 30 CAPSULE in 1 BOTTLE (72162-2382-3) Mefenamic acid Bryant Ranch Prepack 2010-11-19
80425-0306-01 30 CAPSULE in 1 BOTTLE (80425-0306-1) Mefenamic Acid Advanced Rx Pharmacy of Tennessee, LLC 2023-04-06
80425-0306-02 60 CAPSULE in 1 BOTTLE (80425-0306-2) Mefenamic Acid Advanced Rx Pharmacy of Tennessee, LLC 2023-04-06
80425-0306-03 90 CAPSULE in 1 BOTTLE (80425-0306-3) Mefenamic Acid Advanced Rx Pharmacy of Tennessee, LLC 2023-04-06
80425-0423-01 30 CAPSULE in 1 BOTTLE (80425-0423-1) Mefenamic Acid Advanced Rx of Tennessee, LLC 2024-07-19
80425-0423-02 60 CAPSULE in 1 BOTTLE (80425-0423-2) Mefenamic Acid Advanced Rx of Tennessee, LLC 2024-07-19
80425-0423-03 90 CAPSULE in 1 BOTTLE (80425-0423-3) Mefenamic Acid Advanced Rx of Tennessee, LLC 2024-07-19
Observed labelers: Advanced Rx of Tennessee, LLC (3) · Advanced Rx Pharmacy of Tennessee, LLC (3) · Micro Labs Limited (2) · Bryant Ranch Prepack (1) · Lupin Pharmaceuticals, Inc. (1) · Misemer Pharmaceuticals, Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.9590
Range $0.9590–$0.9590 · middle 50% $0.9590–$0.9590 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.